Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes medicines for serious diseases. The company is publicly listed and has built a broad biologics pipeline over decades of research.
The FDA launched two pilots to boost domestic manufacturing: PreCheck selected seven companies for earlier engagement, and a CVM pilot prioritizes animal drug applications with US-made ingredients.
Regeneron announced FDA and EMA review acceptance for cemdisiran in generalized myasthenia gravis and FDA priority review acceptance for garetosmab in fibrodysplasia ossificans progressiva. The garetosmab BLA is supported by Phase 3 OPTIMA trial data showing 94% and 90% reductions in new bone lesions.
Regeneron and Parabilis Medicines entered a research collaboration focused on Antibody-Helicon Conjugates. The deal includes $125 million upfront and financing support and up to $2.2 billion in milestones.
Regeneron said the Phase 3 NIMBLE trial of cemdisiran in generalized myasthenia gravis met primary and key secondary endpoints at week 24. The company said a U.S. regulatory application has been submitted and EU filings are planned for 2026.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
The FDA has accepted Regeneron's biologics license application for garetosmab with priority review, targeting fibrodysplasia ossificans progressiva. A decision is expected by August 2026 based on Phase 3 trial data showing significant reductions in new bone lesions.
The FDA removed the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran for ATTRv-PN, allowing patient enrollment and dosing to resume with enhanced safety monitoring.
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
Regeneron said the FDA accepted its garetosmab BLA for FOP and granted Priority Review, with a decision expected by August 2026. Phase 3 OPTIMA data reported major lesion reductions versus placebo.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780110 |
Compassionate Use of Vonsetamig |
AVAILABLE | |
| NCT07759167 |
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07753148 |
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation |
NOT_YET_RECRUITING | PHASE1 |
| NCT07746388 |
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07715734 |
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07710846 |
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy |
NOT_YET_RECRUITING | |
| NCT07704580 |
Phase 1b/2 Study of IV Sarilumab in Adult With RA |
RECRUITING | PHASE1/PHASE2 |
| NCT07697599 |
Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07685808 |
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes |
RECRUITING | PHASE2 |
| NCT07675824 |
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
